£2m Deltex US, German growth:
This article was originally published in Clinica
Executive Summary
UK haemodynamic monitoring company Deltex Medical is looking to expand its sales and marketing operations in the US and Germany with £2m ($4m) of new capital it has secured. The funds, provided in the form of an equity investment-and-loan package, will come from US private equity firm Nexus Medical Partners, and its German affiliate Medicis Capital Partners. Deltex will use the financing to hire additional management and sales staff for its operations in US and Germany. The countries represent the two largest potential markets for the company's CardioQ monitor, according to Chichester, West Essex-based Deltex.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.